Results 91 to 100 of about 176 (130)
Some of the next articles are maybe not open access.
Annals of Hematology, 2012
Cytogenetic analyses of chronic myelogenous leukemia (CML) have been performed previously in a large number of reports, but systematical research based on large sample sizes from the Chinese population is seldom available. In this study, we analyzed the cytogenetic profiles of 1,863 Philadelphia (Ph)/BCR-ABL-positive CML patients from a research center
Qitian, Mu +7 more
openaire +2 more sources
Cytogenetic analyses of chronic myelogenous leukemia (CML) have been performed previously in a large number of reports, but systematical research based on large sample sizes from the Chinese population is seldom available. In this study, we analyzed the cytogenetic profiles of 1,863 Philadelphia (Ph)/BCR-ABL-positive CML patients from a research center
Qitian, Mu +7 more
openaire +2 more sources
[Two Ph chromosome positive chronic myelogenous leukemia patients with rare bcr/abl fusion gene].
Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2008To investigate the unusual bcr/abl fusion gene structures of two Ph chromosome positive chronic myelogenous leukemia (CML) patients in chronic phase (CP).By using general M- and micro -bcr/abl specific primers respectively, bcr/abl fusion transcripts were detected by reverse transcription-polymerase chain reaction (RT-PCR).
Ya-zhen, Qin +10 more
openaire +2 more sources
Blood, 2012
Abstract Abstract 2832 Co-occurrence of a JAK2 V617F-positive myeloproliferative neoplasm (MPN) with BCR-ABL-positive chronic myelogenous leukemia (CML) in a single patient is rare. Previous reports have suggested that the two disorders may arise independently or within the same clone, but definitive clonal analysis has ...
Eric M. Knoche +6 more
openaire +1 more source
Abstract Abstract 2832 Co-occurrence of a JAK2 V617F-positive myeloproliferative neoplasm (MPN) with BCR-ABL-positive chronic myelogenous leukemia (CML) in a single patient is rare. Previous reports have suggested that the two disorders may arise independently or within the same clone, but definitive clonal analysis has ...
Eric M. Knoche +6 more
openaire +1 more source
Leukemia Research, 1992
We studied the type of bcr-abl mRNA for 34 patients with chronic myelogenous leukemia and analyzed for correlations among the mRNA type, the clinical outcome and the transforming activity using the tumorigenicity assay. There was no difference in the distribution of the mRNA-types (b2-a2 and b3-a2) between clinical phases.
M, Futaki +5 more
openaire +2 more sources
We studied the type of bcr-abl mRNA for 34 patients with chronic myelogenous leukemia and analyzed for correlations among the mRNA type, the clinical outcome and the transforming activity using the tumorigenicity assay. There was no difference in the distribution of the mRNA-types (b2-a2 and b3-a2) between clinical phases.
M, Futaki +5 more
openaire +2 more sources
Cancer Genetics and Cytogenetics, 2006
The case of an 11-year-old child with adult-type chronic myeloid leukemia, Philadelphia (BCR-ABL) positive, reverse transcription-polymerase chain reaction negative for the major, minor, and micro breakpoints is presented. In the course of 3 years, the child failed to respond to treatment with hydroxyurea, refused all therapy for 6 months, was ...
Asher M, Moser +3 more
openaire +2 more sources
The case of an 11-year-old child with adult-type chronic myeloid leukemia, Philadelphia (BCR-ABL) positive, reverse transcription-polymerase chain reaction negative for the major, minor, and micro breakpoints is presented. In the course of 3 years, the child failed to respond to treatment with hydroxyurea, refused all therapy for 6 months, was ...
Asher M, Moser +3 more
openaire +2 more sources
Leukemia, 1989
Despite the major breakthrough in the knowledge of the molecular events underlying the t(9;22) translocation, still no consistent data have been found on the evolution of Ph1 positive CML from the chronic to the accelerated or blastic phase of the disease.
Selleri L. +10 more
openaire +2 more sources
Despite the major breakthrough in the knowledge of the molecular events underlying the t(9;22) translocation, still no consistent data have been found on the evolution of Ph1 positive CML from the chronic to the accelerated or blastic phase of the disease.
Selleri L. +10 more
openaire +2 more sources
Acta Haematologica, 2009
AUogeneic bone marrow transplantation (BMT) is considered to be the only curative therapy for chronic myelogenous leukemia (CML). The cytogenetic marker of CML, the Philadelphia (Ph) chromosome, or the molecular alterations caused by the BCR-ABL gene fusion can be used to monitor the success of treatment.
L, Diekmann +7 more
openaire +2 more sources
AUogeneic bone marrow transplantation (BMT) is considered to be the only curative therapy for chronic myelogenous leukemia (CML). The cytogenetic marker of CML, the Philadelphia (Ph) chromosome, or the molecular alterations caused by the BCR-ABL gene fusion can be used to monitor the success of treatment.
L, Diekmann +7 more
openaire +2 more sources
International Journal of Cancer, 1987
AbstractThe expression of c‐abl, c‐sis, c‐myc and N‐ras oncogenes was examined in 2 lymphoblastoid cell lines, one with Ph1 (PB‐1049) and the other without Ph1 (LN‐1049), both established from a patient with chronic myelogenous leukemia (CML), and in a Ph1‐positive cell line (PB‐1049‐T) derived from a tumor formed after transplantation of PB‐1049 cells
T, Yamada +4 more
openaire +2 more sources
AbstractThe expression of c‐abl, c‐sis, c‐myc and N‐ras oncogenes was examined in 2 lymphoblastoid cell lines, one with Ph1 (PB‐1049) and the other without Ph1 (LN‐1049), both established from a patient with chronic myelogenous leukemia (CML), and in a Ph1‐positive cell line (PB‐1049‐T) derived from a tumor formed after transplantation of PB‐1049 cells
T, Yamada +4 more
openaire +2 more sources
Journal of Clinical Oncology, 2006
6591 Background: AMN107 is a novel, highly selective oral Bcr-Abl inhibitor which is 20–50-fold more potent than imatinib. High response rates with AMN107 were observed in all CML phases post imatinib failure. Methods: Study Aims: Evaluate the efficacy of AMN107in newly diagnosed Ph-positive CML-CP.
E. Jabbour +9 more
openaire +2 more sources
6591 Background: AMN107 is a novel, highly selective oral Bcr-Abl inhibitor which is 20–50-fold more potent than imatinib. High response rates with AMN107 were observed in all CML phases post imatinib failure. Methods: Study Aims: Evaluate the efficacy of AMN107in newly diagnosed Ph-positive CML-CP.
E. Jabbour +9 more
openaire +2 more sources
Blood, 2008
Abstract Specific tyrosine kinase inhibition (TKI) of the bcr-abl fusion protein in Philadelphia chromosome positive chronic myelogenous leukemia (CML) was introduced into general use in 2000 after a plenary abstract presentation to ASH in December 1999.
A. Robert Turner +6 more
openaire +1 more source
Abstract Specific tyrosine kinase inhibition (TKI) of the bcr-abl fusion protein in Philadelphia chromosome positive chronic myelogenous leukemia (CML) was introduced into general use in 2000 after a plenary abstract presentation to ASH in December 1999.
A. Robert Turner +6 more
openaire +1 more source

